Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.131
Neutral
RSI(14)
43.613
Neutral
STOCH(KDJ)(9,3,3)
42.519
Sell
ATR(14)
0.375
High Vlolatility
CCI(14)
-0.890
Neutral
Williams %R
42.093
Buy
TRIX(12,20)
-0.191
Sell
StochRSI(14)
0.000
Sell
Inmode Ltd
INMD13.400USD
-0.350-2.55%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
856.17MMarket Cap
9.23P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Inmode Ltd
Currency: USD Updated: 2026-03-27Key Insights
Inmode Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 16.80.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Inmode Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Inmode Ltd Highlights
StrengthsRisks
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Fairly Valued
The company’s latest PE is 9.23, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.36M shares, decreasing 28.82% quarter-over-quarter.
Held by HOTCHKIS & WILEY
Star Investor HOTCHKIS & WILEY holds 864.14K shares of this stock.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
17.000
Target Price
+23.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Inmode Ltd is 8.46, ranking 30 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 103.85M, representing a year-over-year increase of 6.13%, while its net profit experienced a year-over-year increase of 67.35%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.52
Operational Efficiency
8.49
Growth Potential
8.91
Shareholder Returns
7.41
Inmode Ltd's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Inmode Ltd is 6.12, ranking 169 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 9.23, which is 129.32% below the recent high of 21.17 and 38.40% above the recent low of 5.69.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 68/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Inmode Ltd is 6.75, ranking 163 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 16.00, with a high of 21.00 and a low of 15.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
17.000
Target Price
+23.64%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Inmode Ltd
INMD
7
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Inmode Ltd is 6.19, ranking 154 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 13.96 and the support level at 12.78, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
13.666
Sell
MA10
13.618
Sell
MA20
13.483
Sell
MA50
14.207
Sell
MA100
14.321
Sell
MA200
14.499
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Inmode Ltd is 5.00, ranking 114 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 59.11%, representing a quarter-over-quarter increase of 11.95%. The largest institutional shareholder is James Simons, holding a total of 2.44M shares, representing 3.85% of shares outstanding, with 5.36% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Mizrahy (Moshe)
Kreindel (Michael)
DOMA Perpetual Capital Management, LLC
Acadian Asset Management LLC
Millennium Management LLC
BlackRock Institutional Trust Company, N.A.
Goldman Sachs & Company, Inc.
Systematic Financial Management, L.P.
Meitav Investment House Ltd
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Inmode Ltd is 8.06, ranking 27 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.11
VaR
+5.47%
240-Day Maximum Drawdown
+23.23%
240-Day Volatility
+40.23%
Return
Best Daily Return
60 days
+10.61%
120 days
+10.61%
5 years
+15.51%
Worst Daily Return
60 days
-8.82%
120 days
-8.82%
5 years
-19.97%
Sharpe Ratio
60 days
-0.64
120 days
-0.61
5 years
-0.21
Risk Assessment
Maximum Drawdown
240 days
+23.23%
3 years
+72.28%
5 years
+86.96%
Return-to-Drawdown Ratio
240 days
-0.43
3 years
-0.28
5 years
-0.16
Skewness
240 days
-0.18
3 years
-0.52
5 years
+0.07
Volatility
Realised Volatility
240 days
+40.23%
5 years
+55.24%
Standardised True Range
240 days
+3.29%
5 years
+11.27%
Downside Risk-Adjusted Return
120 days
-91.46%
240 days
-91.46%
Maximum Daily Upside Volatility
60 days
+40.08%
Maximum Daily Downside Volatility
60 days
+41.08%
Liquidity
Average Turnover Rate
60 days
+1.99%
120 days
+2.06%
5 years
--
Turnover Deviation
20 days
-7.90%
60 days
+9.15%
120 days
+12.76%
Peer Comparison
Healthcare Equipment & Supplies
Inmode Ltd
INMD
6.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
